Abstract
Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.
| Original language | English |
|---|---|
| Pages (from-to) | 519-543 |
| Number of pages | 25 |
| Journal | Drugs |
| Volume | 28 |
| Issue number | 6 |
| State | Published - Dec 1 1984 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Health, Toxicology and Mutagenesis
- Toxicology
Cite this
Midazolam. A review of its pharmacological properties and therapeutic use. / Dundee, J. W.; Halliday, N. J.; Harper, K. W.; Brogden, R. N.
In: Drugs, Vol. 28, No. 6, 01.12.1984, p. 519-543.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Midazolam. A review of its pharmacological properties and therapeutic use
AU - Dundee, J. W.
AU - Halliday, N. J.
AU - Harper, K. W.
AU - Brogden, R. N.
PY - 1984/12/1
Y1 - 1984/12/1
N2 - Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.
AB - Midazolam is a short-acting water-soluble benzodiazepine (at pH < 4), a member of a new class of imidazobenzodiazepine derivatives. At physiological pH the drug becomes much more lipid soluble. Water solubility minimises pain on injection and venous thrombosis compared with diazepam administered in organic solvent. Midazolam is a hypnotic-sedative drug with anxiolytic and marked amnestic properties. To date it has been used mostly by the intravenous route, for sedation in dentistry and endoscopic procedures and as an adjunct to local anaesthetic techniques. It has proved less reliable than thiopentone, but preferable to diazepam, as an intravenous induction agent and is unlikely to replace the other well established drugs. However, due to the cardiorespiratory stability following its administration, midazolam is useful for anaesthetic induction in poor-risk, elderly and cardiac patients. The short elimination half-life (1.5-3.5 h) and the absence of clinically important long acting metabolites make midazolam suitable for long term infusion as a sedative and amnestic for intensive care, but clinical trials have yet to be completed. Thus, a combination of properties make midazolam a useful addition to the benzo-diazepine group.
UR - http://www.scopus.com/inward/record.url?scp=0021743129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021743129&partnerID=8YFLogxK
M3 - Article
VL - 28
SP - 519
EP - 543
JO - Drugs
JF - Drugs
SN - 0012-6667
IS - 6
ER -